M
Mark Kunkel
Publications - 8
Citations - 483
Mark Kunkel is an academic researcher. The author has contributed to research in topics: Epigenome & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 377 citations.
Papers
More filters
Journal ArticleDOI
Comprehensive characterization of the Published Kinase Inhibitor Set
Jonathan M. Elkins,Vita Fedele,M. Szklarz,Kamal R. Abdul Azeez,Eidarus Salah,Jowita Mikolajczyk,Sergei Romanov,Nikolai Sepetov,Xi Ping Huang,Bryan L. Roth,Ayman Al Haj Zen,Denis Fourches,Eugene N. Muratov,Alexander Tropsha,Joel Morris,Beverly A. Teicher,Mark Kunkel,Eric C. Polley,Karen Lackey,Francis Atkinson,John P. Overington,John P. Overington,Paul Bamborough,Susanne Müller,Daniel J. Price,Timothy M. Willson,Timothy M. Willson,David H. Drewry,David H. Drewry,Stefan Knapp,Stefan Knapp,William J. Zuercher,William J. Zuercher +32 more
TL;DR: A thorough characterization of the Published Kinase Inhibitor Set is provided and chemical starting points for designing new chemical probes of orphan kinases are identified and the utility of these leads are illustrated by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.
Journal ArticleDOI
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Eric C. Polley,Mark Kunkel,David R. H. Evans,Thomas Silvers,Rene Delosh,Julie Laudeman,Chad Ogle,Russell Reinhart,Michael Selby,John Connelly,Erik Harris,Nicole Fer,Dmitriy Sonkin,Gurmeet Kaur,Anne Monks,Shakun Malik,Joel Morris,Beverly A. Teicher +17 more
TL;DR: Agents targeting nuclear kinases appear to be effective in SCLC lines, and Associating drug response with micro-RNA expression indicated that lines most sensitive to etoposide and topotecan expressed high miR-200c-3p and lowMiR-140-5p and miR -9- 5p, while the BCL-2/BCL-XL inhibitors produced similar response patterns.
Journal ArticleDOI
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.
Beverly A. Teicher,Eric C. Polley,Mark Kunkel,David Evans,Thomas Silvers,Rene Delosh,Julie Laudeman,Chad Ogle,Russell Reinhart,Michael Selby,John Connelly,Erik Harris,Anne Monks,Joel Morris +13 more
TL;DR: The diversity in sarcoma phenotype and genotype make treatment of this family of diseases exceptionally challenging, and comparison of several compounds targeting the same molecular entity allowing comparison of target specificity and heterogeneity of cell line response is presented.
Journal ArticleDOI
Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
Julia Krushkal,Thomas Silvers,William C. Reinhold,Dmitriy Sonkin,Suleyman Vural,John Connelly,Sudhir Varma,Paul S. Meltzer,Mark Kunkel,Annamaria Rapisarda,David Evans,Yves Pommier,Beverly A. Teicher +12 more
TL;DR: Multiple associations indicate potential epigenetic mechanisms affecting SCLC response to chemotherapy and suggest targets for combination therapies.
Journal ArticleDOI
F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd.
Joel Morris,Donn G. Wishka,Lopez Omar D,Vladimir F Rudchenko,Guangfei Huang,Sierra Hoffman,Suzanne Borgel,Kyle Georgius,John Carter,Howard Stotler,Mark Kunkel,Jerry M. Collins,Melinda G. Hollingshead,Beverly A. Teicher +13 more
TL;DR: Canther et al. as mentioned in this paper compared 5-aza-4'-thio-2'-β-fluoro-2"-deoxycytidine (F-azaT-dCyd, NSC801845), a novel cytidine analog, is first disclosed and compared with T-Dcyd, F-Tdcyd and aza-Tcyd in cell culture and mouse xenograft studies in HCT-116, HL-60, and BL-0382.